LexDanaLexDanabeta
Inventor

Nebojsa Janjic

Inventor
Boulder, CO, US

Overview

65→
Patents
1995–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 65 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary
C12NMicroorganisms or enzymes18%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms13%
G01NInvestigating or analysing materials by determining their chemical or physical properties11%
A61KPreparations for medical, dental or toiletry purposes11%
C07HSugars9%
C07KPeptides9%
C40BCombinatorial chemistry8%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations6%
F02BInternal-combustion piston engines5%
B82YSpecific uses or applications of nanostructures4%
PatentTitleYear
10,927,380Oligonucleotides comprising modified nucleosides202110,808,251Nucleic acid compounds for binding growth differentiation factor 11202010,544,419PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders202010,538,771Compositions and methods for detecting microorganisms202010,526,663Method of detecting a microorganism in a sample by a fluorescence based detection method202010,408,847Tuberculosis biomarkers and uses thereof201910,392,621Multiaptamer target detection201910,370,669Nucleic acid compounds for binding growth differentiation factor 8201910,239,908Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto201910,221,421Post-selec modification methods201910,221,2075-position modified pyrimidines and their use201910,093,933Compositions and methods for detecting microorganisms20189,994,857PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders20189,938,314Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto20189,926,566'Multiaptamer target detection'20189,701,967'Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions'20179,695,424'PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders'20179,410,156'Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions'20169,206,429'Aptamers that bind to IL-6 and their use in treating or diagnosing IL-6 mediated conditions'20159,163,056'5-position modified pyrimidines and their use'20159,081,010'Aptamers for clostridium difficile diagnostics'20158,895,241'Aptamers for clostridium difficile diagnostics'20148,697,720'Substituted phenylether-thienopyridone compounds with antibacterial activity'20148,658,670'Methods and compounds for treatment of clostridium based infection'20148,431,376'Bacterial replication systems and methods'20138,071,737'Nucleic acid ligand complexes'20117,994,192'Substituted thienopyridone compounds with antibacterial activity'20117,973,050'Enantiomeric compounds with antibacterial activity'20117,939,654'Platelet derived growth factor (PDGF) nucleic acid ligand complexes'20117,879,993'Platelet derived growth factor (PDGF) nucleic acid ligand complexes'20117,258,980'Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligands'20077,196,069'High affinity RNA ligands of basic fibroblast growth factor'20077,153,948'High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)'20067,094,535'Nucleic acid ligands to integrins'20066,962,784'Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes'20056,762,290'High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors'20046,759,392'High affinity RNA ligands of basic fibroblast growth factor'20046,696,252'High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)'20046,677,146'Thermophilic polymerase III holoenzyme'20046,670,132'Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand'20036,582,918'Platelet derived growth factor (PDGF) nucleic acid ligand complexes'20036,465,188'Nucleic acid ligand complexes'20026,426,335'Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes'20026,344,321'Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met'20026,331,394'Nucleic acid ligands to integrins'20016,329,145'Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand'20016,229,002'Platelet derived growth factor (PDGF) nucleic acid ligand complexes'20016,184,364'High affinity nucleic acid ligands containing modified nucleotides'20016,177,557'High affinity ligands of basic fibroblast growth factor and thrombin'20016,168,778'Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes'20016,147,204'Nucleic acid ligand complexes'20006,051,698'Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes'20006,020,206'Homocysteine assay'20006,011,020'Nucleic acid ligand complexes'20005,958,691'High affinity nucleic acid ligands containing modified nucleotides'19995,859,228'Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes'19995,849,479'High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)'19985,843,732'Method and apparatus for determining consensus secondary structures for nucleic acid sequences'19985,811,533'High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)'19985,723,594'High affinity PDGF nucleic acid ligands'19985,674,685'High affinity PDGF nucleic acid ligands'19975,668,264'High affinity PDGF nucleic acid ligands'19975,660,985'High affinity nucleic acid ligands containing modified nucleotides'19975,639,868'High-affinity RNA ligands for basic fibroblast growth factor'19975,459,015'High-affinity RNA ligands of basic fibroblast growth factor'1995

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1995–2001Patents assigned to NEXSTAR PHARMACEUTICALS INC (17)· patent assignee history
1995–2021Based in Boulder, CO, US· patent location history
1997–2001Based in Lafayette, CO, US· patent location history
2001–2011Patents assigned to GILEAD SCIENCES INC (16)· patent assignee history
2011–2014Patents assigned to JANJIC NEBOJSA (5)· patent assignee history
2011–2014Patents assigned to CRESTONE INC (4)· patent assignee history
2014–2021Patents assigned to SOMALOGIC INC (22)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
SOMALOGIC INC222014–2021
NEXSTAR PHARMACEUTICALS INC171995–2001
GILEAD SCIENCES INC162001–2011
JANJIC NEBOJSAself52011–2014
CRESTONE INC42011–2014
Locations
LocationPatentsSpan
Boulder, CO, US621995–2021
Lafayette, CO, US31997–2001